Reports company had a total cash, cash equivalents, and marketable securities balance of approximately $100.3M at September 30. "The approval of ROLVEDON marks a significant accomplishment for Spectrum and our partner Hanmi Pharmaceutical. We are proud that the product became commercially available in October and are excited to be competing in an estimated $2 billion market opportunity. Importantly, we have been preparing for this milestone and have the financial runway to support ROLVEDON in the marketplace. While we are disappointed by the ODAC vote on poziotinib, we are awaiting the final response from the FDA and will continue to act in the best interest of the Company, our shareholders, and the patients who need our medicines," said Tom Riga, President and CEO of Spectrum Pharmaceuticals.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SPPI:
- Spectrum announces commercial availability of Rolvedon
- Spectrum price target lowered to $6 from $9 at H.C. Wainwright
- Spectrum price target lowered to $1.50 from $4 at B. Riley
- Spectrum: FDA panel votes 9-4 that benefits of poziotinib did not outweigh risks
- FDA Oncologic Drugs Advisory Committee to hold a virtual meeting